Overview of Stem Cell Therapies in Immune System Disorders

Longfei Zhao

doi:10.62051/6n7qc882

Authors

Longfei Zhao

DOI:

https://doi.org/10.62051/6n7qc882

Keywords:

Stem cell therapy, immune system disorders, regenerative medicine.

Abstract

The advent of stem cell technology signifies a novel era in the field of medicine, providing revolutionary therapies for a range of diseases, including immune system disorders. Stem cells have a remarkable ability to regenerate and differentiate into many types of cells, which makes them highly promising for the repair of damaged tissues and organs. The objective of this study is to investigate the capacity of stem cell treatment in addressing immune system disorders. The article examines recent advancements and uses of several types of stem cells in regulating the immune response, restoring injured tissues, and offering long-term solutions for treating immunological-mediated diseases. The study encompasses an extensive examination of stem cell differentiation, immune system disorders, and in-depth case studies that showcase the achievements and difficulties encountered when utilizing stem cells to treat conditions such as rheumatoid arthritis, systemic lupus erythematosus, immune thrombocytopenia, and Crohn's disease. The paper also investigates the methods via which stem cells execute their therapeutic effects, including immune regulation and tissue restoration. The conclusion highlights the substantial advancements achieved in stem cell research and its auspicious prospects in personalized medicine and regenerative therapeutics.

Downloads

Download data is not yet available.

References

[1] MONTAGNANI S, RUEGER M A, HOSODA T, et al. Adult Stem Cells in Tissue Maintenance and Regeneration [J]. Stem Cells Int, 2016, 2016: 7362879.

[2] KARAMI Z, MORADI S, EIDI A, et al. Induced pluripotent stem cells: Generation methods and a new perspective in COVID-19 research [J]. Front Cell Dev Biol, 2022, 10: 1050856.

[3] MAREI H E, KHAN M U A, HASAN A. Potential use of iPSCs for disease modeling, drug screening, and cell-based therapy for Alzheimer's disease [J]. Cell Mol Biol Lett, 2023, 28(1): 98.

[4] DOUEK D C. Disrupting T-cell homeostasis: how HIV-1 infection causes disease [J]. AIDS Rev, 2003, 5(3): 172-7.

[5] THOMSON J A, ITSKOVITZ-ELDOR J, SHAPIRO S S, et al. Embryonic stem cell lines derived from human blastocysts [J]. Science, 1998, 282(5391): 1145-7.

[6] LO B, PARHAM L. Ethical issues in stem cell research [J]. Endocr Rev, 2009, 30(3): 204-13.

[7] BIANCO P, ROBEY P G. Stem cells in tissue engineering [J]. Nature, 2001, 414(6859): 118-21.

[8] CAPLAN A I, BRUDER S P. Mesenchymal stem cells: building blocks for molecular medicine in the 21st century [J]. Trends Mol Med, 2001, 7(6): 259-64.

[9] TAKAHASHI K, YAMANAKA S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors [J]. Cell, 2006, 126(4): 663-76.

[10] OKITA K, ICHISAKA T, YAMANAKA S. Generation of germline-competent induced pluripotent stem cells [J]. Nature, 2007, 448(7151): 313-7.

[11] NUSSE R, CLEVERS H. Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities [J]. Cell, 2017, 169(6): 985-99.

[12] KOPAN R, ILAGAN M X. The canonical Notch signaling pathway: unfolding the activation mechanism [J]. Cell, 2009, 137(2): 216-33.

[13] ALLEMAILEM K S, ALMATROODI S A, ALMATROUDI A, et al. Recent Advances in Genome-Editing Technology with CRISPR/Cas9 Variants and Stimuli-Responsive Targeting Approaches within Tumor Cells: A Future Perspective of Cancer Management [J]. Int J Mol Sci, 2023, 24(8).

[14] DOUDNA J A, CHARPENTIER E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9 [J]. Science, 2014, 346(6213): 1258096.

[15] MCINNES I B, SCHETT G. The pathogenesis of rheumatoid arthritis [J]. N Engl J Med, 2011, 365(23): 2205-19.

[16] FIRESTEIN G S. Evolving concepts of rheumatoid arthritis [J]. Nature, 2003, 423(6937): 356-61.

[17] KIRIAKIDOU M, CHING C L. Systemic Lupus Erythematosus [J]. Ann Intern Med, 2020, 172(11): Itc81-itc96.

[18] COOPER N, GHANIMA W. Immune Thrombocytopenia [J]. N Engl J Med, 2019, 381(10): 945-55.

[19] NEUNERT C, TERRELL D R, ARNOLD D M, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia [J]. Blood Adv, 2019, 3(23): 3829-66.

[20] BAUMGART D C, SANDBORN W J. Crohn's disease [J]. Lancet, 2012, 380(9853): 1590-605.

[21] STRAND V, KIMBERLY R, ISAACS J D. Biologic therapies in rheumatology: lessons learned, future directions [J]. Nat Rev Drug Discov, 2007, 6(1): 75-92.

[22] SMOLEN J S, LANDEWé R B M, BIJLSMA J W J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update [J]. Ann Rheum Dis, 2020, 79(6): 685-99.

[23] THOMAS E D. A history of haemopoietic cell transplantation [J]. Br J Haematol, 1999, 105(2): 330-9.

[24] CAPLAN A I. Mesenchymal stem cells [J]. J Orthop Res, 1991, 9(5): 641-50.

[25] GRATWOHL A, BRAND R, APPERLEY J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) [J]. Haematologica, 2006, 91(4): 513-21.

[26] SARSENOVA M, ISSABEKOVA A, ABISHEVA S, et al. Mesenchymal Stem Cell-Based Therapy for Rheumatoid Arthritis [J]. Int J Mol Sci, 2021, 22(21).

[27] WANG R, YAO Q, CHEN W, et al. Stem cell therapy for Crohn's disease: systematic review and meta-analysis of preclinical and clinical studies [J]. Stem Cell Res Ther, 2021, 12(1): 463.

[28] MURARO P A, PASQUINI M, ATKINS H L, et al. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis [J]. JAMA Neurol, 2017, 74(4): 459-69.

[29] LE BLANC K, MOUGIAKAKOS D. Multipotent mesenchymal stromal cells and the innate immune system [J]. Nat Rev Immunol, 2012, 12(5): 383-96.

[30] DUFFY M M, PINDJAKOVA J, HANLEY S A, et al. Mesenchymal stem cell inhibition of T-helper 17 cell- differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor [J]. Eur J Immunol, 2011, 41(10): 2840-51.

[31] CORCIONE A, BENVENUTO F, FERRETTI E, et al. Human mesenchymal stem cells modulate B-cell functions [J]. Blood, 2006, 107(1): 367-72.

[32] GNECCHI M, ZHANG Z, NI A, et al. Paracrine mechanisms in adult stem cell signaling and therapy [J]. Circ Res, 2008, 103(11): 1204-19.

[33] CAPLAN A I. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine [J]. J Cell Physiol, 2007, 213(2): 341-7.